Learn

Diabetes Research Review Issue 143 with commentary by Professor Mathis Grossmann.  

This review is a unique Australian publication providing topical, relevant and accessible information for health professionals with an interest in Diabetes. In essence, the review is a summary of what we consider to be some of the most significant new studies in this area.

To access this publication please click ‘Enrol Now’ and you’ll be directed to the publication. Then sign up to Research Review at no cost. You can then login with your email and password. If you require any assistance please email Research Review – trish@researchreview.com.au 

Details

In this edition we feature:

• Maridebart cafraglutide reduces bodyweight in obesity
• Efsitora for type 2 diabetes: QWINT-1, 3 and 4
• Cagrilintide-semaglutide for overweight/obesity and type 2 diabetes
• Orforglipron in early type 2 diabetes
• Retatrutide reduces fat mass in type 2 diabetes
• CV events with sulfonylureas vs. DPP-4 inhibitors
• Ophthalmic complications with GLP-1 agonists

To access this publication please click ‘Enrol Now’ and you’ll be directed to  the publication. Then sign up to Research Review at no cost. You can then login with your email and password. If you require any assistance please email Research Review – trish@researchreview.com.au

This activity is accepted by CPD Home as Domain 1: Educational Activity - Professional Reading in alignment with the CPD Home Program Guide. 

Disclaimer: Please note, once you click 'Enrol now' you will be leaving the AMA’s CPD Home website and entering a third-party website.